Connect with us

Business

First Indian woman journalist to take coronavirus vaccine Pooja Makkar says ‘she is completely fine’ after 20 hours.

Published

on

Zee News reporter Pooja Makkar, who became the first Indian woman journalist to receive the indigenously developed coronavirus vaccine ‘Covaxin’, said on Tuesday that she is completely fine and normal.

Speaking with channel in live interaction, Pooja Makkar said, “It has been 20 hours since I took the coronavirus vaccine – Covaxin. I am completely fine. I am completely normal.” Seeking to dispel rumours about the indigenously developed coronavirus vaccine, she urged people not to believe in those rumours. “It (vaccine) is completely safe. There is nothing to worry about it. I urge people to have faith in the government. This vaccine has been developed to keep the people of Indian safe,” Pooja Makkar said.

When asked about any physical or internal impact post-vaccination, she bravely stated in front of the camera that she is “not having any problem so far.” Pooja Makkar became the first female journalist to get coronavirus vaccine, Covaxin, in India on Monday. Covaxin is the indigenous vaccine developed by Bharat Biotech against COVID-19 in collaboration with ICMR.

Pooja Makkar got vaccinated at AIIMS, Delhi in the afternoon at 2 PM after the requisite tests. She remained under observation and shared her experience later. The Zee News reporter, who is a health reporter, has extensively reported about the COVID-19 pandemic and its fallout besides keeping a tab on the vaccines being developed in the country to tackle this deadly virus.

Earlier talking about her experience, Pooja said that after 5.30 hours she has not felt any complication, adding that she decided to undergo the vaccination as “it was necessary to instill confidence among common people that the vaccine is fully safe.”

Pooja has been provided a sheet to fulfill the points asked about her experience. She has also been provided with a helpline number to contact AIIMS in case she confronted any problem in the coming days.

After 28 days, she will get another shot of Covaxin as this is needed twice to remain safe against the deadly pandemic. Pooja remained on the frontline while covering all aspects related to the deadly virus. Notably, the Drugs Controller General of India (DCGI) has recently provided emergency use approval of the two coronavirus vaccines.

Covaxin, the indigenous vaccine developed by Bharat Biotech against COVID-19 in collaboration with ICMR, is 200 percent safe, the company`s Chairman and Managing Director Dr Krishna Ella had said. He further said that it has shown less than 10 percent adverse reaction in trials so far.

Dr Ella’s remarks came a day after DGCI granted permission for the restricted emergency use of Covaxin. The indigenous vaccine has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

In a release earlier, Bharat Biotech had earlier said that Covaxin is a highly purified and inactivated two-dose SARS-CoV2 vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses.

Earlier on Sunday, COVID-19 vaccines of Serum Institute of India and Bharat Biotech were granted permission for restricted use in an emergency situation by the Drugs Controller General of India (DCGI).

 

Automobile

Here are top five selling cars in India right now: Watch list

Published

on

The Maruti Suzuki Vitara Brezza was the largest-selling sub-4metre compact SUV in India in March 2021. It was followed by the Hyundai Venue, Mahindra Bolero, Tata Nexon and Kia Sonet. Let us have a look at the sales numbers of all these models for the month of March 2021.

Maruti Suzuki Vitara Brezza – 11,274 units

Continuing its hold over the sub-4metre compact SUV segment, the Maruti Suzuki Vitara Brezza emerged as the best-seller with sales of 11,274 units in March 2021. It is priced between 7.51 lakh and Rs 11.41 lakh (ex-showroom, Delhi).

Hyundai Venue – 10,722 units

Following the Maruti Suzuki Vitara Brezza was the Hyundai Venue with sales of 10,722 units in March 2021. The Venue is available in the price range of Rs 6.87 lakh to Rs 11.67 lakh (ex-showroom, Delhi).

Mahindra Bolero – 8,905 units

The third best-selling sub-4metre compact SUV in March 2021 was the Mahindra Bolero with sales of 8,905 units. It is offered in the price bracket of Rs 8.17 lakh to Rs 9.14 lakh (ex-showroom, Delhi).

Tata Nexon – 8,683 units

At the fourth position was the Tata Nexon with sales of 8,683 units in March 2021. The Nexon’s price starts at Rs 7.10 lakh and goes up to Rs 12.79 lakh (ex-showroom, Delhi).

Kia Sonet – 8,498 units

The fifth and final position on the list of the top five best-selling compact SUVs in March 2021 was occupied by the Kia Sonet, which registered sales of 8,498 units. Its price ranges from Rs 6.79 lakh to Rs 13.19 lakh (ex-showroom, Delhi).

Continue Reading

Trending